Effect of OTX-101 0.09% ciclosporin solution on clinical signs of dry eye disease in patients with moderate-to-severe corneal damage: a post-hoc analysis of randomized clinical trials
Administration of OTX-101 0.09% leads to statistically significant improvement across six parameters in ocular surface staining and tear production in DED patients with moderate to severe corneal damage.
Authors
- Elisabeth M. Messmer (ORCID: https://orcid.org/0000-0003-1299-3882)
- Maurizio Rolando (ORCID: https://orcid.org/0000-0002-4982-1462)
- M. Cebollero
- José Manuel Benítez del Castillo
Institutions
- Hospital Clínico San Carlos (ES)
- Joint Research Centre (IT)
- Western Digital (Netherlands) (NL)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- Graefe s Archive for Clinical and Experimental Ophthalmology
- Published
- 2025-12-20
- DOI
- https://doi.org/10.1007/s00417-025-07054-7
- Primary Topic
- Ocular Surface and Contact Lens
- Type
- article
- Field-Weighted Citation Impact
- 0.00